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Both terms, ectopia and heterotopia, are used interchangeab-
ly; they include all tissues and organs that are located distant 
from their correct localization within the body. Examples are 
gastric mucosal ectopia, endometriosis, deciduosis, and ext-
rauterine ectopic pregnancy [1]. The lymph nodes are com-
mon sites for ectopic tissue. Over the past few decades, lymph 
node excision and sentinel lymph node examination have be-
come crucial for microstaging of malignant tumors. There-
fore, knowledge of these aberrant inclusions is indispensable 
to differentiate between micrometastases and benign ectopic 
inclusions. The following article provides an overview of the 
various nodal inclusions and defines the characteristics rele-
vant to a differential diagnosis, here with a special emphasis 
on dermatopathologic considerations. The article is mainly 
intended as a discussion of pathophysiological aspects of no-
dal inclusions and in particular of nodal melanocytic nevi 
from a morphological and immunohistochemical perspecti-
ve, in order to shed light on the topic in a later step using 
molecular genetic methods.
General aspects of aberrant intranodal 
inclusions – What can be found within 
lymph nodes?
In general, a distinction between epithelial, glandular, 
and nonepithelial nodal inclusions can be made. Nong-
landular inclusions are much less common. Depending on 
the lymph node station, there are a number of typical tu-
mors that can colonize a lymph node station. Nevus cells 
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are typically observed in cervicoaxillary and inguinal 
lymph nodes [2]; decidua, which is mainly found in intra-
abdominal lymph nodes, can be confused with metastatic 
squamous carcinoma [3–5], and nodal leiomyomatosis in 
abdominal lymph nodes of patients can be mistaken for 
disseminated peritoneal leiomyomatosis or uterine lei-
omyomas [6, 7]. Benign inclusions in axillary lymph no-
des are the most common cause of false positive diagnoses 
in sentinel lymph node biopsies (SNLB) or lymph node 
dissections [8].
The following inclusions are typically found within axil-
lary lymph nodes:
– Nodal melanocytic nevi (NMN) in 0.33 % of lumpec-
tomy specimens and up to 6.2 % of lymph node resec-
tions performed for malignant melanoma [9–12]
– Epithelial cysts [13, 14]
– Heterotopic mammary glands [8]
In addition to glandular or nonglandular lymph node 
inclusions, miscellaneous materials can be found within the 
lymph node. Pulitzer et al. described the occurrence of solar 
elastotic material in dermal lymphatics and lymph nodes; this 
material was localized within capsules, subcapsular sinuses, 
and parenchyma of lymph nodes of nine patients, from which 
eight had melanoma and one Merkel cell carcinoma. They 
found this elastotic material within the nodes in metastatic 
melanoma, in nodal nevi, and in nodes without any extrinsic 
cell [15].
Interestingly, the following distinct intrinsic and extrin-
sic materials can be found within lymph nodes:
– Cosmetic and tattoo inks [15–17]
– Colloid material used in lymphology studies of flow rate 
and capacitance [16, 18, 19]
– Polyethylene particles remaining after primary joint 
replacement [20, 21]
– Silicone after breast implants [22]
Pulitzer et al. have already critically discussed the para-
digm of general pathology: the existence of extrinsic cells or 
heterotopic tissue within lymph nodes is inseparable from the 
metastatic stage of malignant tumors. Hence, they proposed 
the existence of some benign and clinically irrelevant passive 
nodal “metastases” [15].
The main diagnostic challenge is to differentiate benign 
nodal inclusions from metastatic settlements of primary solid 
tumors such as melanoma or breast cancer. Misdiagnosis can 
lead to extensive surgery, inadequate staging, and overtreat-
ment [8]. Morphologic differentiation in the case of glandu-
lar nodal inclusions can be made because of the absence of 
carcinoma in the primary gland of origin, the appearance of 
normal epithelium, the absence of atypia and mitotic activity, 
the largely intracapsular location of a few glands, and the 
absence of desmoplasia [2].
Endosalpingiosis, most commonly observed in glandu-
lar inclusions, is an example of localization-typical glandular 
inclusions in lymph nodes. It is frequently (5–41 %) seen in 
the pelvic and retroperitoneal lymph nodes of women, whe-
reas it occurs only rarely in supradiaphragmatic lymph nodes 
[8]. Cases of endosalpingiosis within axillary and inguinal 
lymph nodes have been observed very rarely [2, 8]. Sampson 
introduced the term endosalpingiosis in 1930 [23]; it is de-
fined as the heterotopic occurrence of glandular proliferation 
of the scattered remnants of the epithelium of the Mülleri-
an ducts, with differentiation into fallopian tube epithelium 
[8]. The terms “paramesonephric” or “Müllerian inclusions 
with tubal-type epithelium” are used interchangeably [24]. 
Associated stromal tissue is seen in endometriosis, and the 
coincident occurrence of smooth muscle tissue is defined as 
endomyometriosis [24, 25].
The inclusion of mesothelial cells is exceedingly rare 
and most often seen in infradiaphragmatic lymph node sta-
tions such as mediastinal, para-aortic, pelvic, and inguinal 
lymph nodes [2], while salivary glands and thyroid follicles 
occur within cervical lymph nodes [14, 26], colonic glan-
dular tissue, and renal tissue [15, 27, 28]. The intranodal 
inclusions of mesothelial cells tend to be associated with 
hyperplasia and inflammation of the associated serous 
membranes, as evidenced by the presence of associated ef-
fusions. Mesothelial cells imitate sinus histiocytosis or me-
taplastic carcinoma but lack in impingement on the nodal 
structure [2].
Differential diagnoses of diverse heterotopic nodal inclu-
sions in the context of mesothelial tissue in general pathology 
differ because of the underlying histogenesis of original tis-
sue. A distinction is possible by using a larger panel of im-
munohistochemical stains [2]. Differential diagnoses of nodal 
mesothelial inclusions include metastatic melanoma (S100+, 
HMB45+), nodal melanocytic nevi (S100+, HMB45–), and 
carcinoma, especially in the case of serious borderline tumors 
with subcapsular sinusoidal pattern of involvement (cytoke-
ratin+, MOC-31 antibody+, also known as epithelial-specific 
antigen/Ep-CAM) [2, 29, 30]. Further differential diagnoses 
include anaplastic large cell lymphoma (which can in turn 
also be stained with epithelial markers) [31, 32] and – the 
most challenging – metastatic mesothelioma [33]. Because 
immunohistochemistry cannot distinguish between benign 
and malignant, the differentiation of benign mesothelial cells 
and metastatic mesothelioma depends on distinct criteria, 
and this distinction is sometimes extremely difficult. Intri-
guingly, mesothelioma usually does not show marked aty-
pia, whereas benign inclusions may show atypia and mitotic 
activity [34, 35]. A cytological evaluation or biopsy of the 
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suspected mesothelial surfaces may distinguish between the 
two types [2].
Nodal melanocytic inclusions – nodal 
melanocytic nevi
Nodal melanocytic nevi (NMN) were first recognized in 
1931 by Stewart and Copeland and defined as melanocytic 
nevocellular inclusions within lymph nodes; they noted that 
NMN were always incidental findings [36]. Mostly, these are 
bland nevus cell aggregates that resemble the nevocellular 
cells found in the intradermal part of cutaneous nevi. Ho-
mogeneous eosinophilic cytoplasm and unremarkable mela-
nin pigment, indistinct cytoplasmic borders, and nearly no 
mitotic activity are the accepted morphologic characteristics 
of NMN [11] (Figure 1a–c). The morphologic similarities 
between cutaneous melanocytic nevi and NMN are the main 
reasons why most authors believe that these are basically be-
nign [11]. Recently, Gonzàlez-Farré et al. proposed a classi-
fication of NMM nevi into three types and explained their 
associated diagnostic difficulties [37]:
	 Intraparenchymal nevus in a patient with invasive 
melanoma
	 Nodal nevus adjacent to a melanoma micrometastasis 
within the same sentinel node
	 Nodal blue nevus in a patient with malignant melanoma
In our opinion, a fourth type of nodal melanocytic in-
clusion is missing from this list: those that are found in the 




Figure 1 Small nodal nevus aggregates typically located within the fibrous capsule of a lymph node. Small nests consisting of 
monomorphous melanocytic cells are seen (hematoxylin-eosin stain [HE], original magnification x 100) (a). Nodal melanocytes 
usually do not express HMB45; this can be used as adjunct in distinction between benign and malignant (HMB45 stain, origi-
nal magnification x 100) (b). Melan A expression proving melanocytic differentiation (Melan A stain, original magnification 
x 100) (c). Regular capsule area of a small subcutaneous lymph node with tender fibrous capsule and some histiocytes within 
subcapsular sinus (HE, original magnification x 100) (d). Extremely small aggregates of nodal nevus presenting as a small layer 
of spindle shaped melanocytes within a fibrous capsule (HE, original magnification x 100) (e). Please note, extensive adjunct 
immunohistochemistry is not possible due to very limited morphologic correlate (Melan A stain, original magnification x 100) 
(f). Same lesion of nodal nevus (g–i). Heavily pigmented nodal nevus resembling nodal blue nevus (HE, original magnification 
x 100) (g). Missing expression argues against the diagnosis of nodal blue nevus (HMB45 immunohistochemistry, original magni-
fication x 100) (h); Melan A stain, original magnification x 100 (i).
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tumor entities, such as breast cancer or squamous cell car-
cinoma of the head and neck area. Lymph nodes with nevus 
complexes are also found in these tumors, albeit much less 
frequently than in sentinel lymph nodes from patients with 
melanoma [38, 39].
Despite well-defined morphological criteria and modern 
immunohistochemical staining techniques, the differentiati-
on of NMN from metastatic melanoma remains difficult or 
even impossible in individual cases. This is especially true in 
the context of nodal inclusions of blue nevi, where the dis-
tinction between benign and malignant is already challen-
ging concerning the primary cutaneous tumor, so a residual 
uncertainty will remain. In such cases, it is imperative that 
the dermatopathologist obtains a second opinion report. The 
aim is to avoid patient overtreatment and undertreatment 
because of an incorrect interpretation of nodal melanocytic 
inclusions. To be able to assess the nodal cell proliferation in 
terms of their dignity reliably, it is recommended to compare 
the nodal cell morphology with the primary tumor lesion. If 
morphology and immune phenotype in the primary and no-
dal infiltrate are the same, there is a high probability that the 
same lesion is present in the lymph node. This applies to both 
metastases of melanoma and “relocations” of a congenital 
nevus cell nevus [39, 40].
Location of nodal melanocytic nevi
The regular capsule area of a subcutaneous lymph node with 
a tender fibrous capsule and some histiocytes within the sub-
capsular sinus is shown in Figure 1d. Nodal melanocytic nevi 
are predominantly located within this area of fibrous capsule 
and trabeculae and rarely within nodal parenchyma and si-
nusoids of superficial lymph nodes drained from skin (Figu-
re 1a–c and g–i). The occurrence of nodal nevus within pe-
rinodal vessels is also a known phenomenon [41, 42]. Ogawa 
et al. detected parts of NMN partly within a lymph node hi-
lus [43]. An axillary lymph node extirpation in the context of 
breast cancer was required and melanoma was unknown at 
the time of the axillary lymph node operation. In this respect, 
on the one hand, the complex of melanocytic cells, which in-
itially appeared to be intraparenchymal, was diagnosed as a 
colonization of melanoma, and only further diagnostic steps, 
including immunohistochemistry and extended dermatologi-
cal assessment of the patient, allowed for the diagnosis of a 
nodal nevus, which was presented in the step sections in the 
lymph node hilus [43].
Characteristically, NMN are found in superficial lymph 
nodes; the deep abdominal and pelvic lymph node stations 
do not have these inclusions [10, 11, 39, 44]. The location 
of NMN is a “soft” but very important criterion to differen-
tiate between benign nevus or metastatic nodal melanoma 
[37]. Although many studies consider trabecular or capsular 
location as a criterion for benignity, if melanocytic cells ap-
pear within the lymph node parenchyma, it is mandatory to 
consider metastatic melanoma.
A study by Biddle et al. described 13 patients who un-
derwent neck dissection and axillary and inguinal lymph 
node extirpation in the context of a malignant disease [39]. 
The patients suffered partly from melanoma and partly from 
breast cancer, tonsil carcinoma, and adnexal carcinoma. In 
all patients, individual lymph nodes could be detected in 
all the stations mentioned, which had nevus cell aggregates 
within the lymph node parenchyma. Mitoses could not be 
detected, and there were no prominent vacuoles or lympho-
vascular invasion [39].
Incidence of nodal melanocytic nevi (NMN) and 
their association to congenital cutaneous nevi
For benign and malignant diseases, NMN are observed 
with an incidence of 1–22 % [9–12], while the occurrence of 
NMN is higher in lymph nodes from patients with melano-
ma compared with those who have breast or prostate cancer 
[11]. In a huge data analysis of 11,274 patients by de Beer 
et al., an incidence of intranodal nevi within sentinel nodes 
of 5 % was found [45]. Additionally, Holt et al. found a dif-
ferent incidence in sentinel nodes from melanoma patients 
compared with non-sentinel nodes from melanoma patients 
(1 %) with higher rates of NMN in sentinel nodes (3.9 %) 
[11]. The occurrence of NMN correlates significantly with 
an increase of Breslow’s thickness of malignant melanoma 
greater than 2.5 mm and is also associated with the existen-
ce of associated cutaneous nevi (75 %), especially nevi with 
congenital features (19 %) [11]. Nodal melanocytic nevi are 
usually not observed in non-sentinel lymph nodes of melano-
ma patients [11].
The occurrence of melanoma associated with congenital 
melanocytic nevi adjacent to primary melanoma leads to hig-
her incidences of NMN in these cases [9–11]. Additionally, 
these NMN are more frequent in cases of melanoma arising 
from a preexisting nevus than de novo melanoma, as well as 
in cases where small congenital nevi are located in the corre-
sponding draining area of the skin [9, 10].
In the first description by Stewart and Copeland, a nodal 
nevus was described in a patient whose melanoma occurred 
within a large congenital nevus and who also had neurofi-
bromatosis [36]. In 1974, McCarthy et al. published a case 
series with NMN associated with cutaneous nevi, presenting 
an extremely high percentage of patients who displayed this 
association (21 out of 22 patients with congenital nevi display-
ed NMN in corresponding regional skin areas) [44]. In both 
series from Fontaine et al. (2002) and Carson et al. (1996), 
this association of NMN and congenital nevi of the skin ad-
jacent to primary melanoma was examined, and a significant 
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association between both was found [9, 10]. Carson et al. de-
monstrated that 40 % of all lymph nodes from patients with 
melanoma arising in a nevus showed nodal nevus inclusions, 
while in cases of de novo melanoma, only 20 % of the lymph 
nodes had nodal nevus complexes [9]. Fontaine was able to 
show a significant association between the presence of cuta-
neous nevi in corresponding zones of the skin with nodal nevi 
and a significant association of the presence of congenital nevi 
with nodal nevi [10].
Lymph node extirpation represents a special situation in 
patients with large to giant congenital nevi; these patients 
have a significantly increased risk of developing malignant 
melanoma within the congenital nevus [46, 47]. A few reports 
of the occurrence of nodal nevi in patients with melanoma 
arising in a giant congenital nevus have been described [40, 
48, 49]. However, all published cases have different starting 
situations (none of the children had a nevus-associated mela-
noma, and some balloon cell-like nevus cell populations were 
described, which could also be found in the associated lymph 
nodes) [40]. Furthermore, prophylactic lymphadenectomies 
and sentinel extirpations were carried out [48, 49]; one year 
after diagnosis, all the nodal inclusions were present, and the 
children were still alive and well. Therefore, the cases are 
only comparable to a limited extent, especially because the 
immunohistochemical findings were not congruent. Hara 
et al. described a two-year-old boy with a giant congenital 
nevus of the right abdomen, buttocks, and legs; this was 
surgically removed together with three subcutaneous lymph 
nodes, which were accidentally recorded and assessed. These 
showed large pericapsular, capsular, and trabecular, perisi-
nusoidal nevus aggregations that were positive for HMB45 
[48]. Thus, this case must remain ambiguous regarding the 
dignity of the lymph node inclusions.
Impact of nodal melanocytic nevi on the 
survival of melanoma patients
The ectopic tissue within lymph nodes raises several concerns, 
especially for a dermatopathologist and general pathologist, 
because most nodal inclusions are incidentally found. After 
the correct interpretation of these tissue inclusions within the 
clinical and oncologic context, the fear remains that on the 
one hand, confusion of benign and malignant nodal inclu-
sions may occur, greatly impacting patients in their further 
treatment (over- and undertreatment). Additionally, there is 
the fear of overlooking metastatic settlements because of de-
flections by nodal inclusions. An impressive example of this 
is reflected by nodal pigmentation because of ornamental tat-
toos. Recently, we showed that nodal pigmentation by tattoo 
pigment does not influence the survival of melanoma patients 
[17]. Meanwhile, cases of NMN have also been checked se-
veral times to determine whether they may affect the survival 
of melanoma patients.
Gambichler et al. showed that nodal nevus cell aggrega-
tes do not affect the prognosis of melanoma patients, with 
a 5-year disease-free survival of these patients correspon-
ding to that of those without nodal nevi [50]. Smith et al. 
confirmed these data, showing that patients with intranodal 
nevi can be treated just like sentinel node negative patients. 
Furthermore, they observed a significant survival benefit for 
patients with intranodal nevi compared with sentinel no-
de-positive patients or patients with isolated nodal tumor 
cells [51]. Finally, de Beer et al. performed an evaluation of 
data from the Dutch Nationwide Network and Registry of 
Histopathology and Cytopathology (PALGA) and confir-
med that there seems to be no difference in survival between 
patients with intranodal nevi and those who are sentinel 
negative [45].
Nodal blue nevus
In the meantime, numerous reports on the appearance of no-
dal blue nevi have been published. Begum et al. showed a case 
of combined blue nevus and benign common nevus within a 
sentinel node of a patient with invasive duct carcinoma of 
the breast but with no evidence for cutaneous melanoma in 
her history. Two of the four excised sentinel nodes did show 
nodal blue nevus within the extension in the nodal fibrous 
capsule and trabeculae [52]. The authors justified their dia-
gnosis of nodal blue nevi with the sparse proliferative activi-
ty with Ki67 and the benign cytomorphology. HMB45 was 
positive in metastatic cells and in nodal blue nevus cells [52]. 
Most of the cases published are difficult to interpret becau-
se they describe blue nevus cells with expression of HMB45 
within the sentinel nodes of melanoma patients. Because of 
the localization of melanocytic cells to the capsule and nodal 
trabeculae, a lack of atypia and of resemblance to primary 
tumor lesions, these tumors are assessed as nodal blue nevi. 
This must at least be critically examined.
Interpretation of nodal melanocytic 
inclusions and its impact on diagnosis
False-negative sentinel lymph node interpretation has been 
reported in less than 5 % of cases and probably occurs becau-
se of pre-laboratory processes from the performance of prior 
biopsies altering the lymphatic drainage including the inex-
perience of the surgeon and failure of the detection technique 
used [38]. The misinterpretation of immunohistochemical 
stains must be noted because inadvertent immunostaining is-
sues can occur [38], and nonspecific antibody stains can also 
lead to interpretation errors. Scognamiglio et al. attached 
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great importance to careful interpretation of sentinel nodes 
in clinical oncology, calling it “the need for vigilance in the 
pathologic evaluation of sentinel lymph node” [53].
“False positive” cells in sentinel nodes of melanoma pa-
tients are also possible. This term describes the case when 
the inclusions of melanocytic cells are found in sentinel 
lymph nodes from non-melanoma patients. Thus, not all 
melanocytic cells with a characteristic lineage differentiati-
on in immunohistology correspond to metastatic melanoma. 
For example, Melan A–positive cells have also been detec-
ted in sentinel lymph nodes from patients with breast cancer 
without a history of melanoma [54]. Hypothetically, these 
“false positive” cells can be explained as nodal nevus cells, 
non-melanocytic cells with cross-reacting antigenic determi-
nants, melanophages that present melanocytic antigens, or 
melanocytes or melanocytic stem cells that are released on 
the skin at the time of the surgical intervention and are enri-
ched within the lymph node via lymphatic vessels [54].
Hopeful adjuncts for differential diagnostics of 
nodal melanocytic nevi
Although cytomorphology seems to be the most helpful tool 
to distinguish between benign nevus cell inclusions and no-
dal metastatic cells of malignant melanoma [37], abundant 
immunostains are available to support conventional morpho-
logy in doubtful cases. Immunohistochemistry for S100, Ty-
rosinase, SOX10, and Melan A/MART-1 cannot distinguish 
between nodal nevus and nodal melanoma.
Ambiguous situations in which the nodal nevi are diffi-
cult to distinguish from melanoma on morphologic grounds 
are the following:
–	 Intraparenchymatous or sinusoidal proliferations of me-
lanocytic cells, mainly in single cell formation
–	 Atypical cytomorphologic criteria (mitoses, vacuolated 
cells)
–	 Atypical immunohistochemistry (for example HMB45 
positivity) without the possibility of comparison with 
primary melanoma
Detailed knowledge of the staining evidence of the vari-
ous antibodies is imperative to avoid diagnostic pitfalls in the 
analysis of sentinel lymph node biopsy from melanoma pa-
tients in the context of NMN. One of the biggest secondary 
problems in the diagnosis of nodal nevi is tissue loss during 
technical processing of tissue due to the variety of necessary 
immunostains and the mostly small lesion size of NMN (Fi-
gure 1e, f).
Table 1 enumerates selected promising stains that 
may help differentiate between nevus and metastatic cells 
due to differential expression in nevus cells and metastatic 
melanoma: Primary and metastatic melanoma display dif-
fuse cytoplasmatic expression of PRAME, whereas NMM 
does not express PRAME [55]. For a detailed summary of 
the specific expression characteristics of PRAME in the 
various melanocytic lesions, we refer to the comprehensive 
work of Cecilia Lezcano from 2018 [56]. PRAME expressi-
on was found in 87 % of metastatic melanoma and 83.2 % 
of primary melanoma whereas 86.4 % of all nevi examined 
were negative for PRAME [56]. PRAME expression is seen 
in all subtypes of malignant melanoma (nodular, superficial 
spreading as well as desmoplastic melanoma). It should be 
mentioned, however, that Lezcano also found that 13.6 % 
of cutaneous nevi including all subtypes (common acquired, 
traumatized, Spitz and dysplastic nevi) did show immunore-
activity for PRAME [56]. Moreover, Raghavan et al. showed 
diffuse expression of PRAME in benign and atypical Spitz 
nevi [57]. These possible pitfalls, as well as the expression 
of PRAME in many other solid organ tumors and sarcoma 
severely limit the use of this antibody for diagnosis of ma-
lignancy and especially for distinction of benign nodal me-
lanocytic deposits in the context of malignant melanoma.
Mib1 is generally expressed at a much lower level in no-
dal nevi than in melanoma (ranging from 0–5 %), although 
metastatic melanoma is consistently positive for Mib1 [39, 
58]. A distinct difference in staining pattern was shown by 
Kanner et al. with reticulin staining groups of nodal me-
tastatic melanoma but surrounding individual nodal me-
lanocytic cells of nodal nevus inclusions [59]. NM23, a me-
tastasis-suppressor gene, did not show any distinct staining 
that could distinguish between benign and malignant types 
[59].
The relevance of HMB45 in the context of NMN is 
not straightforward, and there are important limitations. 
Forty percent of nodal melanoma metastases did not express 
HMB45 [60]; thus, negative staining does not exclude me-
lanoma [60, 61]. Conversely, a positive stain with HMB45 
is not automatically a sign for malignancy because diverse 
benign cutaneous nevi and blue nevi express HMB45 [62]. 
Thus, concerning the differentiation of nodal nevus and me-
tastatic melanoma, there is an urgent need to use a panel of 
distinct immunostains. Chen et al. proved that nestin and 
Sox2 are useful markers to differentiate between nodal nevi 
and metastatic melanoma [63]. Nestin is expressed in mela-
noma and much less in nodal nevi. SOX2 is not expressed 
in nodal nevi but is expressed in melanoma [63]. Expression 
of fatty acid synthase (FASN) in malignant melanoma and 
melanoma metastases (cutaneous and nodal) has been de-
scribed by Innocenzi et al. in 2003. They proposed FASN as 
a reliable prognostic marker in human melanomas [64]. But 
even in this work, FASN expression was not specific for mela-
noma or metastasis [64]. Additionally, Kapur et al. reported 
FASN expression as being highly specific for melanoma and 
Review Review on ectopic nodal inclusions
1151© 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft. | JDDG | 1610-0379/2021/1908
Table 1 Characteristics of selected immunohistochemical markers that may help differentiate between benign and malignant.
Antibody Expression characteristics Special comments on 







expressed antigen in 
melanoma)
–  Member of the family of can-
cer testis antigens
–  Expression in normal tissue: 
testis, ovary, placenta, adren-
als, endometrium
–  Expression in cutaneous me-
lanoma, ocular melanoma, 
various non-melanocytic 
malignant neoplasms (for ex-
ample uterine carcinosarcoma, 
synovial sarcoma, and lei-
omyosarcoma, non-small cell 
lung cancer, breast carcinoma, 
renal cell carcinoma and many 
others)
–  Malignant melano-
ma displays diffuse 
nuclear labeling for 
PRAME
–  Cutaneous nevi are 
mainly negative for 
PRAME
–  Spitz nevi and blue 
nevi were not exa-
mined in Lezcano 
et al. (1)
–  But: Benign and 
atypical Spitz nevi do 
express PRAME (2)
[87–92]




–  FASN expression is observed 
in some normal human tissues 
and highly proliferative lesions 
in carcinoma, for example 
colon, breast and ovary carci-
noma
–  FASN/ACC expres-




–  No expression in 
NMN






–  Loss of 5-hydroxymethylcytosi-
ne is known as epigenetic hall-
mark of human malignancy
–  Independent predictor of 
worse prognosis in melanoma, 
gastric cancer, hepatocellular 
carcinoma and more
–  Due to dysfunction of the 
tumor-suppressive ten-ele-
ven translocase (TET) family 
of enzymes and active DNA 
demethylation pathway
–  Expression in me-
lanocytic nevi
–  Metastatic melano-
ma does not express 
5-hydroxymethylcy-
tosine
–  Dysplastic nevi and 




p16 –  Tumor suppressor protein in-
volved in the regulation of cell 
cycle and senescence
–  Loss of p16 expression is seen 
in several human malignan-
cies, for example melanoma
–  Nuclear and cyto-
plasmatic expression 
in dermal and nodal 
nevi
–  Melanoma metasta-
ses are mostly negati-
ve or display different 
staining pattern than 
nevi
–  Staining pattern (nuc-
lear vs. cytoplasmatic 
vs. weak nuclear and 
diffuse cytoplasmatic) 
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melanoma metastases with stronger expression in melanoma 
with a higher Clark level. Nevertheless, they also observed 
an expression of FASN in benign congenital nevi [65]. In the 
work by Saab et al., FASN and ACC (acetyl-CoA carboxyla-
se) were reliably positive in metastatic melanoma and negati-
ve in nodal nevi [60]. In this work, NMN displayed negativi-
ty for FASN and ACC in all cases examined with a sensitivity 
and specificity of 100 % while HMB45 showed sensitivity of 
60 % and specificity of 100 % in identification of melanoma 
metastases and distinction of nodal melanocytic nevi [60]. 
Lee et al. introduced 5-hydroxymethylcytosine expression 
as an adjunct marker for differentiation because it stained 
positive in nodal nevi and negative in all melanoma cases ex-
amined [66]. p16 also can serve as a useful marker for diffe-
rentiation because it is expressed mainly in nevi of all kinds, 
cutaneous as well as nodal, while cells of melanoma metas-
tases lacked nuclear staining for p16 [67, 68]. Mihic-Probst 
et al. examined the staining pattern of p16 in nodal and der-
mal melanocytic nevi and melanoma metastasis. They pro-
pose p16 as a useful additional marker for differentiation of 
nevi and melanoma metastases based on its staining pattern 
[67]. However, in our opinion, the staining pattern is diffi-
cult to assess (nuclear vs. cytoplasmatic vs. weak nuclear and 
diffuse cytoplasmatic) and it is far from unambiguous. p16 
cannot be used on its own, but only in a panel of different 
antibodies.
In summary, the expression of p16 and 5-hydroxy-
methylcytosine is seen in cells of nodal nevi and lacks ex-
pression in metastatic melanoma. In contrast, FASN, ACC, 
Mib1, PRAME, Nestin, and SOX2 are expressed mainly in 
melanoma, but not in nodal nevi.
For everyday histopathology we use and recommend the 
regular application of an antibody panel made from an anti-
body cocktail (Dako DuoFLEX Cocktail, anti-S100, anti-ty-
rosinase, anti-Melan A; Code IC001) and HMB45 for rou-
tine stains of lymph nodes in a setting of known cutaneous 
melanoma. Herewith primarily melanocytic deposits that are 
most often seen in hematoxylin-eosin stain, can be visualized 
as well. The differential expression of HMB45 facilitates the 
primary differentiation of metastatic deposits. Further im-
munohistochemical stains are carried out individually. Most 
nodal deposits can be characterized with this approach.
To distinguish between metastatic melanoma and nodal 
nevus, a fluorescence in-situ hybridization (FISH) examina-
tion, in addition to conventional and immunohistochemical 
examinations, seems ideal. Although a FISH examination 
cannot replace a histomorphological assessment, it is a hel-
pful adjunct with a sensitivity of 83 % [69]. Dalton et al. 
confirmed that vigorous expression of HMB45 indeed shows 
a high specificity of melanoma or metastatic nodal inclusi-
ons of the same primary type. A significantly improved in-
terpretation of these findings can be achieved if, in addition 
to the nodal melanocytic inclusions, the primary melanoma 
can also be examined when searching for mutations. Cases 
in which the nodal deposit shows no genetic aberration that 
corresponds to the primary melanoma can be regarded as no-
dal nevus inclusions [69].
Theories on the histogenesis of nodal 
inclusions
Several theories on the genesis of ectopic tissue in lymph no-
des are currently being discussed, but none of them is ulti-
mately satisfactory, especially for nodal melanocytic inclusi-
ons. For endosalpingiosis, the following modes of genesis are 
being discussed: surgical displacement [70], peritoneal im-
plantation of sloughed tubal epithelium [70], dissemination 
of tubal mucosa via lymphatics [23], Müllerian metaplasia of 
pelvic peritoneal mesothelium and submesothelium and the 
subsequent formation of benign glands (endosalpingiosis), or 
carcinomas resembling those of the ovary and fallopian tube 
[8]. Entrapment of remnants during embryologic develop-
ment and Müllerian-type inclusions that are thought to arise 
from embryologic remnants of coelomic epithelium are also 
possible modes of pathogenesis [2].
Pathophysiology of nevus aggregates 
within lymph nodes
There are currently two different theories addressing the 
question of how nevus cells reach lymph nodes. Both are un-
satisfactory and explain by no means all clinical variations of 
nodal nevi [10, 11, 71]:
– The theory of benign metastasis: embolic transfer of cuta-
neous melanocytic cells via lymphatics from skin to the 
corresponding lymph node [9, 72].
– Migration arrest theory: Nodal nevomelanocytes arise 
from a melanocyte precursor cell with aberrant embryo-
logic migration en route from the neural crest to destined 
cutaneous location via the dorsolateral pathway [10, 72, 
73].
In our opinion, it is likely that there is more than one 
correct answer and more than one explanation for nodal ne-
vus inclusions. In our view, there is only a handful of convin-
cing arguments for or against one theory or the other. Hence, 
the theory of migration arrest does not explain why nodal 
nevi are seen with higher frequency in sentinel nodes from 
melanoma patients than in other primary tumors.
In general, causes for nodal inclusions of any kind can 
be explained by the transport of all manner of cells through 
lymphatics to the draining lymph node; this is mainly favored 
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for colonic glands, renal epithelium, urothelium, some me-
lanocytic nevi, and endometriosis [25]. The occasional ap-
pearance of extrinsic tissue within lymph nodes is well do-
cumented. Even acellular to paucicellular solar elastotic 
material can be found within lymph nodes [15]. Passive me-
chanical transport or trauma may play an important role in 
many cases of ectopic and heterotopic nodal tissue inclusions.
Regarding the occurrence of nodal inclusions of breast 
tissue, two options are discussed: the spreading of tumor 
cells, because of prior surgery, by mechanical passage of 
tumor cells via the lymphatic system and collection in the 
lymph nodes, and breast massage as part of the sentinel node 
biopsy [74]. A trauma-associated genesis because of an ear-
lier surgery to remove a primary melanoma has also been 
discussed regarding nodal melanocytic cell aggregates.
Although this rather mechanistic theory appears logical 
it has considerable weaknesses. It is highly unlikely that the 
time between surgery of a primary malignant melanoma and 
the subsequent sentinel lymph node biopsy is long enough 
that any mechanically washed out cutaneous melanocytic 
cells can be flushed into the lymph nodes via the lymphatic 
system, settle there, and form nodal nevus aggregates. This 
theory would only explain scattered solitary tumor cells wit-
hin the sentinel lymph node. This would, however, be the op-
posite of a benign process (no “benign metastases”); instead, 
it would – by paradigmatic definition – be the start of tumor 
cell dissemination by the underlying malignant tumor within 
the corresponding lymphatic area.
The flushing out of benign nevomelanocytes through 
lymphatic channels is well described. Sood et al. described 
the case of a young boy with an intradermal melanocytic ne-
vus and with evidence of intralymphatic nevus cell emboli, 
and they discussed the concept of a nevus resulting from be-
nign metastasis [75]. As early as 1979, Bell et al. described 
a series of cases of dermal nevus cell nevi with evidence of 
intralymphatic nevus cell nests [76]. Although this phenome-
non was rarely observed and published for common dermal 
nevi, it was repeatedly observed in Spitz nevi, with Howat 
et al. reporting a frequency of 14.3 % [77]. According to 
the thesis of benign metastasis, and the frequent observation 
of lymphatic nevus cell embolism by Spitz nevi, one would 
expect increased nodal inclusions of melanocytic cells in sen-
tinel lymph nodes or lymph node extirpation in the context of 
spitzoid cutaneous lesions. Surprisingly, this is not the case. 
On the contrary, Caraco et al. studied 40 cases of atypical 
Spitz nevi retrospectively. In none of the cases melanocytic 
inclusions were found in the lymph node, either benign in 
nature as a nodal Spitz nevus, or as metastatic settlement 
[78]. The theory of benign metastases is supported by the 
finding of circulating benign nevus cells in the blood display-
ing the dissemination of nevus cells via lymphatics as well as 
with blood [79]. Leblebici et al. supported the mechanical 
theory of benign metastasis in lymph nodes; they observed 
intralymphatic nevus cell aggregates in 13 out of 369 (3.5 %) 
benign cutaneous nevi. All nevi examined displayed protrusi-
ons of nevus cells inside lymphatics independently of the exis-
tence of intralymphatic nevus cell aggregates [80]. Protrusi-
ons of the nevus cells inside lymphatics may be the precursor 
step to intralymphatic nevus cell aggregates because these 
findings closely depend on the tissue sections investigated. 
However, for solitary nevus cells to settle in the lymph node, 
it will most likely take more time than a few days or weeks.
Change of a paradigm?
To make matters worse, the theory of benign metastasis, at-
tacks one fundamental pathological paradigm, namely the 
paradigm that the sowing of tissue via lymphatic tissue in 
lymph nodes represents a classic defining criterion of malig-
nancy. The theory of benign and clinically irrelevant metas-
tasis, a thesis that Pulitzer et al. proposed against the back-
ground of the sowing of elastotic material in lymph nodes 
[15], is more than plausible from a mechanistic point of view, 
but it must consequently lead to a paradigm shift in clini-
cal-pathological oncology.
Spatial and temporal aspects speak against the theory of 
benign metastasis in the case of nodal nevi without cutaneous 
nevi in lymphatic corresponding skin areas and against the oc-
currence of the traumatically or mechanically induced settle-
ment of disrupted cutaneous nevus cells within lymph nodes in 
the setting of sentinel lymph node biopsy. The concept of benign 
metastases may be the leading explanation for non-melanocytic 
ectopic tissues and the incidental occurrence of nodal nevi in 
non-melanoma patients, but it is not for NMN in the context of 
sentinel node biopsy because of malignant melanoma.
A simple explanation for this could be the fact that me-
lanoma patients show on average more than twice as many 
melanocytic nevi compared to control subjects of the same 
age and sex [81]. Thus, it can be discussed that a higher fre-
quency of melanocytic nevi in the context of melanoma justi-
fies a higher probability for melanocytic nevus cells being 
transported to lymph nodes.
The occurrence of primary extracutaneous melanoma 
(for instance, mucosal melanoma of the head and neck regi-
on or genitalia, urinary tract, or esophagus and biliary tract) 
and meningeal or choroidal melanoma [82] provoke the ques-
tion why NMN do not occur in the deeper visceral lymph 
node stations as well. Higher frequencies of nodal nevi in 
the superficial lymph nodes of patients with malignant cuta-
neous melanoma are historically explained by the concept of 
benign metastases or migration arrest. In consequence, nodal 
nevi would also be possible within the lymph nodes of the 
deep visceral compartment. However, there have been no re-
ports on this up to now.
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If melanoblastic cells are able to migrate also to the small 
intestine (ileum) via the omphalomesenteric canal [82] and re-
present the cells of origin of primary melanomas of the gast-
rointestinal tract [83], one should have expected many more 
case reports on nodal nevi in visceral lymph nodes to have 
been published. Ectopic melanocytes are one possible expla-
nation for development of melanoma of an unknown primary 
origin [83, 84]. However, the differentiation of melanocytes 
from pre-existing pluripotent stem cells of distinct sites (e.g., 
lymph nodes, visceral organs) could also be imagined.
The “sleeping ectopic melanoblast”
Here, we propose another, more extraordinary unifying 
concept of nevogenesis in lymph nodes in patients with me-
lanoma, which we would like to name sleepy ectopic me-
lanoblast theory. This means the hypothetical coexistence of 
primary ectopic melanocytes – via migration arrest – and 
ectopic pluripotent stem cells in all the compartments menti-
oned above (in which extracutaneous melanoma may occur) 
would explain all clinical and histomorphological aspects of 
nodal nevi, especially their higher frequency of occurrence 
within sentinel nodes. The concept of the lymph node as a 
premetastatic niche supports our theory [85]. Consequently, 
in melanoma, there may be certain circumstances involving 
a kind of occult induction of the expression of prometastatic 
growth factors and cytokines, along with factors that induce 
remodeling of the extracellular matrix within lymph nodes. 
These conditions might favor pathways leading to altered 
plasticity of melanoblasts and ectopic single cells that have 
settled within the lymph node since early development and 
beyond, inducing proliferation and differentiation toward 
nodal nevus or – beyond the lymphatic transport of tumor 
cells – also malignant transformation of these resident me-
lanoblastic cells.
Based on the widely accepted fact that precursor cells 
of melanoblasts and of the neurogenic population are gli-
al-melanocytic bipotent progenitors with the ability to dif-
ferentiate into distinct cell lines [86], it is, in our opinion, in 
the range of the conceivable that these nodal ectopic and/or 
pluripotent melanocytic precursor cells are activated in a dif-
ferential mode. This may be either via distinct driver muta-
tions characteristic for cutaneous melanomas or by factors 
released by the primary cutaneous melanoma, resulting in 
subsequent differentiation towards nodal nevoid aggregates 
in all types of nodal compartments independently of afferent 
lymphatics.
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